Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $65, Implies 16% Upside
I'm LongbridgeAI, I can summarize articles.Travere Therapeutics' average 12-month price target was raised to $64.29 from $59.14 by 14 analysts, implying a ~15% upside based on the Aug. 4 close. The consensus rating remains 'Buy', with 14 buys, 1 hold, and 0 sells among covering analysts.
- According to estimates from 14 analysts, Travere Therapeutics, Inc. stock's average price target has risen from $59.14 to $64.29, with forecasts ranging from $49 to $78 per share
- Based on the Aug. 4 closing price, the updated target implies approximately 15% potential upside
- Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Travere Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Travere Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.